Eric A Mellon1,2, William H Jin1, Jessica M Frakes1, Barbara A Centeno3, Tobin J Strom1, Gregory M Springett4, Mokenge P Malafa4, Ravi Shridhar5, Pamela J Hodul4, Sarah E Hoffe1. 1. a Department of Radiation Oncology , H. Lee Moffitt Cancer Center and Research Institute , Tampa , Florida , USA. 2. b Department of Radiation Oncology , University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center , Miami , Florida , USA. 3. c Department of Pathology , H. Lee Moffitt Cancer Center and Research Institute , Tampa , Florida , USA. 4. d Gastrointestinal Tumor Program , H. Lee Moffitt Cancer Center and Research Institute , Tampa , Florida , USA. 5. e Department of Radiation Oncology , Florida Hospital Cancer Institute , Orlando , Florida , USA.
Abstract
BACKGROUND: Neoadjuvant therapy response correlates with survival in multiple gastrointestinal malignancies. To potentially augment neoadjuvant response for pancreas adenocarcinoma, we intensified treatment with stereotactic body radiotherapy (SBRT) following multi-agent chemotherapy. Using this regimen, we analyzed whether the College of American Pathology (CAP) tumor regression grade (TRG) at pancreatectomy correlated with established response biomarkers and survival. MATERIALS AND METHODS: We identified borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer patients treated according to our institutional clinical pathway who underwent surgical resection with reported TRG (n = 81, median follow-up after surgery 24.2 months). Patients had baseline CA19-9, computed tomography (CT), endoscopic ultrasound, and FDG positron emission tomography (PET)/CT then underwent multi-agent chemotherapy (79% with three cycles of gemcitabine, docetaxel and capecitabine) followed by 5-fraction SBRT. They then underwent restaging CT, PET/CT and CA19-9. Overall (OS) and progression-free (PFS) survival were estimated and compared by Kaplan-Meier and log-rank methods. Univariate ordinal logistic regression correlated TRG with baseline, restaging and change in CA19-9 and the PET maximum standardized uptake value (SUVmax). RESULTS: Restaging level and decrease in CA19-9 correlated with improved TRG (p = .02 for both) as did restaging SUVmax (p < .01), yet there was no TRG correlation with decrease in SUVmax (p = .10) or CT response (p = .30). The TRG groups had similar OS and PFS except the TRG 0 (complete response) group. Compared to partial response levels (TRG 1-3, median OS 33.9 months, median PFS 13.0 months), the six (7%) patients with TRG 0 had no deaths (p = .05) and only one progression (p = .03). A group of 10 (12%) TRG 1 patients with only residual isolated tumor cells had similar outcomes to the other TRG 1-3 patients. CONCLUSION: Pre-operative PET-CT and CA19-9 response correlate with histopathologic tumor regression. Patients with complete pathologic response have superior outcomes, suggesting a rationale for intensification and personalization of neoadjuvant therapy in BRPC and LAPC.
BACKGROUND: Neoadjuvant therapy response correlates with survival in multiple gastrointestinal malignancies. To potentially augment neoadjuvant response for pancreas adenocarcinoma, we intensified treatment with stereotactic body radiotherapy (SBRT) following multi-agent chemotherapy. Using this regimen, we analyzed whether the College of American Pathology (CAP) tumor regression grade (TRG) at pancreatectomy correlated with established response biomarkers and survival. MATERIALS AND METHODS: We identified borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancerpatients treated according to our institutional clinical pathway who underwent surgical resection with reported TRG (n = 81, median follow-up after surgery 24.2 months). Patients had baseline CA19-9, computed tomography (CT), endoscopic ultrasound, and FDG positron emission tomography (PET)/CT then underwent multi-agent chemotherapy (79% with three cycles of gemcitabine, docetaxel and capecitabine) followed by 5-fraction SBRT. They then underwent restaging CT, PET/CT and CA19-9. Overall (OS) and progression-free (PFS) survival were estimated and compared by Kaplan-Meier and log-rank methods. Univariate ordinal logistic regression correlated TRG with baseline, restaging and change in CA19-9 and the PET maximum standardized uptake value (SUVmax). RESULTS: Restaging level and decrease in CA19-9 correlated with improved TRG (p = .02 for both) as did restaging SUVmax (p < .01), yet there was no TRG correlation with decrease in SUVmax (p = .10) or CT response (p = .30). The TRG groups had similar OS and PFS except the TRG 0 (complete response) group. Compared to partial response levels (TRG 1-3, median OS 33.9 months, median PFS 13.0 months), the six (7%) patients with TRG 0 had no deaths (p = .05) and only one progression (p = .03). A group of 10 (12%) TRG 1patients with only residual isolated tumor cells had similar outcomes to the other TRG 1-3 patients. CONCLUSION: Pre-operative PET-CT and CA19-9 response correlate with histopathologic tumor regression. Patients with complete pathologic response have superior outcomes, suggesting a rationale for intensification and personalization of neoadjuvant therapy in BRPC and LAPC.
Authors: Patrick M McCarthy; Matthew J Rendo; Matthew D Uy; Alexandra M Adams; Anne E O'Shea; Daniel William Nelson; Joshua L Fenderson; Katherine M Cebe; Robert W Krell; Guy T Clifton; George E Peoples; Timothy J Vreeland Journal: Onco Targets Ther Date: 2021-06-01 Impact factor: 4.147
Authors: Alex B Blair; Lauren M Rosati; Neda Rezaee; Georgios Gemenetzis; Lei Zheng; Ralph H Hruban; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Joseph M Herman; Jin He Journal: Surgery Date: 2018-03-12 Impact factor: 4.348
Authors: Jin He; Alex B Blair; Vincent P Groot; Ammar A Javed; Richard A Burkhart; Georgios Gemenetzis; Ralph H Hruban; Kevin M Waters; Justin Poling; Lei Zheng; Daniel Laheru; Joseph M Herman; Martin A Makary; Matthew J Weiss; John L Cameron; Christopher L Wolfgang Journal: Ann Surg Date: 2018-07 Impact factor: 13.787
Authors: Naomi M Sell; Grace C Lee; Carlos Fernández-Del Castillo; Cristina R Ferrone; Andrew L Warshaw; Theodore S Hong; Lawrence S Blaszkowsky; Keith D Lillemoe; Motaz Qadan Journal: Pancreas Date: 2020-08 Impact factor: 3.243